Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Blazing Star Merger Sub, Inc. has launched tender offers for any and all outstanding notes of Walgreens Boots Alliance (NASDAQ: WBA) and Walgreen Co., spanning multiple series with various interest rates and maturities from 2025 to 2050. The tender offers are accompanied by consent solicitations to modify certain indenture provisions.
The tender offer includes an Early Tender Payment of $50 (or €50/£50 for European notes) per $1,000 principal amount for holders who tender by August 4, 2025. The offer expires on August 18, 2025, with settlement expected on August 19, 2025. This initiative is directly connected to WBA's pending acquisition via merger with Blazing Star Parent, LLC.
Walgreens (NYSE:WBA) has announced a new healthcare collaboration with Premier Medical to establish in-store medical clinics in Central Florida. The partnership will initially launch with two clinics opening in July 2025 in Davenport and Orlando, Florida.
The clinics will provide primary care, chronic condition management, and dermatology services to patients with Medicare, Medicare Advantage, commercial, and select Medicaid plans. Premier Medical, part of NeueHealth, plans to expand with additional clinic locations later in the year.
Walgreens Boots Alliance (Nasdaq: WBA) shareholders have overwhelmingly approved the company's acquisition by Sycamore Partners, with 96% of total votes and 95% of unaffiliated shareholder votes in favor of the merger agreement.
Under the deal terms, shareholders will receive $11.45 per share in cash at closing, plus a non-transferable Divested Asset Proceeds Right for up to an additional $3.00 per share from the future monetization of WBA's interests in VillageMD. The transaction is expected to close in Q3 or Q4 of 2025, pending regulatory approvals.
Walgreens Boots Alliance (NASDAQ:WBA) reported disappointing Q3 fiscal 2025 results, with sales increasing 7.2% to $39.0 billion but posting a loss of $0.20 per share compared to earnings of $0.40 in the year-ago quarter. Adjusted EPS fell to $0.38 from $0.63 last year.
The company's performance was marked by weakness in U.S. front-end sales, with retail sales declining 5.3%. However, pharmacy sales increased 11.8% and comparable pharmacy sales grew 14.6%. The U.S. Healthcare segment showed improvement, turning an adjusted operating loss of $22 million last year into a $54 million profit.
Notably, WBA has entered into a definitive agreement to be acquired by Sycamore Partners, with the transaction expected to close in Q3 or Q4 of calendar year 2025. As a result, the company has withdrawn its fiscal 2025 guidance.
Walgreens (WBA) has opened a new micro-fulfillment center (MFC) in Brooklyn Park, Minnesota, expanding its automated prescription processing network. The facility will support nearly 200 Midwest stores, including 145 in Minnesota, and is expected to process approximately 13 million prescriptions annually. The center will create over 175 local jobs.
This addition brings Walgreens' MFC network to 12 facilities nationwide, supporting over 5,000 stores and processing more than 3.5 million prescriptions weekly. The network has shown impressive results, including a 24% year-over-year increase in shipped volumes and managing approximately 40% of prescription volume for supported stores. The initiative also includes an environmental focus, having recycled 3.7 million pounds of materials in fiscal 2024.
Walgreens (WBA) has announced comprehensive support measures for Rite Aid customers and employees affected by Rite Aid's bankruptcy and store closures. For customers, Walgreens is offering seamless prescription transfers through Walgreens.com/transferRX or via phone at 1-833-961-1642. For impacted Rite Aid employees, Walgreens is actively recruiting through dedicated channels, including a phone line (833-Join-Wag) and email (JoinOurStores@walgreens.com).
The company will host virtual informational sessions for pharmacy staff and promises to recognize eligible Rite Aid employees' service time. Walgreens offers career growth opportunities through programs like PharmStart, tuition assistance, and Student Loan 401(k) Match, while utilizing micro-fulfillment centers to enhance patient care time.
Walgreens (WBA) announces its participation in National Prescription Drug Take Back Day on April 26, 2025, promoting safe disposal of unused or expired medications. The company maintains over 1,500 disposal kiosks across 46 states and Washington, D.C., offering this service year-round at no cost during regular pharmacy hours.
The initiative, part of Walgreens' ongoing commitment to combat prescription drug abuse, has successfully collected and properly disposed of more than 6.5 million pounds of unused prescription medications since its inception in 2016. Stores without kiosks offer alternative disposal options like DisposeRx free of charge. All collected medications are safely incinerated at DEA-registered facilities.
Walgreens has launched PharmStart, a groundbreaking fully-funded online education program in partnership with Guild to help eligible team members meet pharmacy school prerequisites. The initiative aims to strengthen the pharmacist talent pipeline by removing financial barriers to pursuing a PharmD degree.
The program's initial cohort includes over 300 team members across six states: Oklahoma, Texas, Oregon, Illinois, Wisconsin and Kentucky. PharmStart was developed in response to a survey highlighting tuition costs and time constraints as major obstacles for pharmacy technicians.
Complementing this initiative, Walgreens offers additional support through its Pharmacy Educational Assistance Program (PEAP) providing up to $40,000 in tuition assistance, and the Student Loan 401(k) Match Program which helps team members earn full matches while paying off student loans.